Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

Summary

The objective of this study is to explore the efficacy of ixekizumab in treating patients with a diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid-dependent anterior uveitis who had failed treatment with a classic synthetic DMARD including methotrexate, mycophenolate, cyclosporin, azathioprine, cyclophosphamide and/or at least one anti-TNF agent including adalimumab, infliximab, etanercept, golimumab or certolizumab.

Timeline

Start

2022-06-01

Primary completion

2024-12-30

Completion

2024-12-30

Drugs

Indications